Oxular’s leadership is committed to developing treatments that are truly life-changing for patients suffering from sight-threatening diseases. The company is well positioned to drive its future growth as a clinical-stage retinal therapeutics development company.
Oxular is in clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME). It is also developing its product pipeline for other indications, while building its team to support future clinical trials and expanded R&D activities.
Oxular’s development pipeline includes treatments for retinal diseases, such as diabetic macular edema and macular degeneration, as well as programs for rare and orphan conditions, including ocular cancers and delivery of gene therapies.